Answer
Mirvetuximab soravtansine (Elahere) is contraindicated in patients with hypersensitivity to the active substance or any excipient listed in section 6.1.
Sources for this answer
- ELAHERE 5 mg/mL concentrate for solution for infusionAbbVie Ltd · emc · SmPC §4.3 Contraindications · Version 2Document updated
Sources checked